Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 8, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced plans to...
-
Mar 1, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Feb 1, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Jan 31, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced initiation...
-
Jan 10, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced corporate...
-
Jan 5, 2022
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the...
-
Jan 4, 2022
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the...
-
Jan 3, 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Dec 7, 2021- 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a clinical...
-
Nov 30, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Nov 29, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its plans...
Nov 15, 2021- Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business...
-
Nov 1, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Oct 18, 2021- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that...
-
Aug 30, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Aug 10, 2021- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business...
-
Aug 2, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
Jul 12, 2021
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock at a public offering price of $17.25 per share,...
-
Jul 7, 2021
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before...
-
Jul 6, 2021
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA...
-
Jun 28, 2021‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical protocol threshold of approximately 60% or greater plasma S-adenosyl methionine (SAM) pharmacodynamic (PD) reduction to initiate IDE397 tumor biopsy cohort for evaluation of tumor PD markers
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updates for...
-
May 24, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
-
May 10, 2021- Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor for MTAP-deletion patients
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business...
-
May 10, 2021- Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of 2 evaluable MUM patients, including a partial response in a 3L patient with a 54% tumor reduction who is awaiting a confirmatory scan
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced dose...
-
May 6, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its...
